If you follow fitness or longevity content, you have seen these names: BPC-157 for tendon and gut healing, TB-500 for recovery, MOTS-c for metabolism, semax for focus, epitalon for anti-aging. They are sold as vials of powder, often labeled research use only, and the labeling is doing legal work rather than describing anyone's actual intent.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven of these peptides. The votes it took, and the announcements that followed, produced one of the more confusing weeks in a market that was already confusing.
What the committee actually voted on
The committee was asked a narrow question: should these substances be added to what is called the 503A bulks list, the roster of ingredients a compounding pharmacy is permitted to use when the ingredient has no other qualifying route.
It recommended yes for six: BPC-157, KPV, TB-500, MOTS-c, semax and epitalon. It recommended no for emideltide, also called DSIP. The votes were close, most carrying at least one abstention, and every one of them went against what FDA's own reviewers had recommended in writing.
One detail that most coverage dropped: each peptide was considered in two chemical forms, free base and acetate salt, so the panel actually took fourteen votes rather than seven.
Nothing became legal on July 24
The 503A bulks list is not a press release, it is federal regulation, codified at 21 CFR 216.23. Today it contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. Not one is a peptide.
Adding a substance requires notice-and-comment rulemaking. That has not started for any of these seven. A pharmacy compounding with BPC-157 today stands in exactly the legal position it stood in on July 22.
The pace is worth sitting with. The last completed cycle ran from advisory committee meetings in 2015 to a proposed rule in December 2016 to a final rule effective March 2019, roughly four years. And FDA issued a second proposed rule in September 2019 to add five more substances. That one has never been finalized. It has been pending nearly seven years.
Anyone telling you these peptides are about to be legal is not describing this process.
FDA's scientists said no, in writing, on all seven
Before the meeting, FDA staff published a briefing document containing fourteen numbered positions, one per substance and form. Each reads the same way: FDA is proposing that this substance not be included on the 503A bulks list.
The reason given, repeatedly, is an absence of data rather than a judgment call about risk tolerance. In FDA's published safety notes on these peptides, the recurring findings are missing human exposure data, immunogenicity concerns, impurity profiles and an inability to characterize what the substance even is from batch to batch.
FDA's Russell Wesdyk put the characterization problem plainly at the meeting: you will see many many different forms, and the agency cannot create quality standards until it knows what the substance is.
Two committee members who voted no said the quiet part out loud. Dr. Elizabeth Rebello of MD Anderson Cancer Center said she was concerned the panel was responding to market induced demand rather than a decision based in solid science. Dr. Brian Lee of the Keck School of Medicine of USC said the endorsement could be potentially harmful and that he could not in good conscience vote yes.
What the human evidence actually shows
We ran an independent literature search alongside FDA's review, and the two agree closely. The honest summary is that for the uses people buy these peptides for, human evidence is close to absent.
BPC-157. One small randomized trial exists, in ulcerative colitis, delivered as an enema rather than by injection. Forty-six people completed it. The difference between the BPC-157 group and placebo had a confidence interval running from -4.84 to 1.62, which crosses zero. That is a null result, not a positive one. FDA found no study administering BPC-157 to humans by the oral, injected, nasal or transdermal routes that consumers actually use.
TB-500. This is where the most common error in peptide content lives. There are seven genuine human trials of thymosin beta-4, a 43-amino-acid protein. TB-500 is a 7-amino-acid fragment. They are different molecules, and the trials of one are not evidence for the other. FDA flags this conflation specifically, and the company that nominated TB-500 made the error itself.
MOTS-c. Several papers describe randomized trials, which sounds encouraging until you read them. Every one measured MOTS-c that people's own bodies produced, as a marker of exercise or metformin response. No human has been given MOTS-c as a drug in a published trial.
KPV. FDA has identified no human exposure data by any route. Our search found no human clinical trials.
Epitalon and semax. The epitalon human literature we found addresses retinitis pigmentosa, not insomnia or aging. Semax has a small Russian-language clinical literature that has not been replicated elsewhere.
If you compete in sport, this is a separate and immediate problem
BPC-157 and TB-500 are both prohibited at all times, in and out of competition, under the 2026 World Anti-Doping Code. This applies to school, collegiate and organized amateur competition that follows the code, not only to professionals. There is no therapeutic use pathway here, because there is no approved therapeutic use.
What we would want a family member to know
The pitch for these compounds leans on real problems: pain that has not resolved, recovery that takes longer than it used to, energy that is not what it was. Those are worth taking seriously, and they deserve a real workup rather than a vial from an unregulated seller.
If you are dealing with a tendon or joint injury that is not healing, that is a question for a clinician who can image it. If it is fatigue or weight, ask about thyroid, iron, B12, vitamin D and A1c, because those are common, testable and treatable. If you are already using a peptide, tell your clinician. They are not there to judge you, and the interaction and reaction risks are unknown enough to be worth naming out loud.
Frequently asked questions
Did the FDA approve BPC-157? ▼
No. BPC-157 has never been approved as a drug in any country. FDA states this directly in its own July 2026 briefing document. The advisory committee vote was a non-binding recommendation about whether pharmacies may compound with it, which is a different question from approval and did not change anything by itself.
Is BPC-157 legal to buy right now? ▼
It is not on the list that would allow a compounding pharmacy to lawfully use it, and it is not an approved drug. Products sold online as research use only are outside the system that regulates medicines. The July 2026 vote did not change this.
When will these peptides be legal for compounding? ▼
No date exists. Adding a substance requires formal rulemaking that has not begun. For scale: the last completed cycle took about four years, and a proposed rule issued in September 2019 to add five other substances has still not been finalized nearly seven years later.
If a peptide gets added to the list, does that mean it is safe and FDA approved? ▼
No, and the regulation says so explicitly. 21 CFR 216.23(d) states there are inadequate data to demonstrate the safety or efficacy of any drug compounded with any listed substance, and that representing such a drug as FDA approved makes it misbranded under federal law.
Is TB-500 the same as thymosin beta-4? ▼
No, and this confusion is the most common error in peptide marketing. Thymosin beta-4 is a 43-amino-acid protein with a real human trial record. TB-500 is a 7-amino-acid fragment. Human trials of thymosin beta-4 are not evidence for TB-500, a point FDA raises specifically.
Will BPC-157 or TB-500 make me fail a drug test? ▼
Both are prohibited at all times under the 2026 World Anti-Doping Code, in and out of competition. Any testing program that follows the code covers them.
